Literature DB >> 16212684

Interpreting patient/informant discrepancies of reported cognitive symptoms in MS.

D A Carone1, R H B Benedict, F E Munschauer, I Fishman, B Weinstock-Guttman.   

Abstract

Although numerous studies have shown that brain-damaged patients tend to underestimate neuropsychological (NP) impairment when self-ratings are compared to informant ratings, the meaning of such discrepancies is not well studied in multiple sclerosis (MS). We compared patient self- and informant-report questionnaire ratings of NP functioning in 122 MS patients and 37 age- and education-matched normal controls. In addition to completing the Multiple Sclerosis Neuropsychological Questionnaire (MSNQ), participants underwent NP testing and assessment of depression, personality, and neuropsychiatric symptoms. Based on the normal distribution of discrepancy scores, patients were classified according to whether they overestimated or underestimated their cognitive ability, relative to informant ratings. ANOVAs comparing test scores derived from overestimators, underestimators, and accurate estimators were significant for multiple measures of cognitive function, depression, personality, and neuropsychiatric symptoms. Overestimators were characterized by less depression and conscientiousness, and greater degrees of cognitive impairment, euphoric behavioral disinhibition, and unemployment as compared to underestimators. We conclude that patient/informant discrepancy scores on the MSNQ are associated with the aforementioned neuropsychiatric features, and that the MSNQ has potential utility for predicting euphoria and disinhibition syndromes in MS.

Entities:  

Mesh:

Year:  2005        PMID: 16212684     DOI: 10.1017/S135561770505068X

Source DB:  PubMed          Journal:  J Int Neuropsychol Soc        ISSN: 1355-6177            Impact factor:   2.892


  29 in total

Review 1.  Reliability and validity of neuropsychological screening and assessment strategies in MS.

Authors:  Ralph H B Benedict; Robert Zivadinov
Journal:  J Neurol       Date:  2007-05       Impact factor: 4.849

2.  Self-assessment in schizophrenia: Accuracy of evaluation of cognition and everyday functioning.

Authors:  Felicia Gould; Laura Stone McGuire; Dante Durand; Samir Sabbag; Carlos Larrauri; Thomas L Patterson; Elizabeth W Twamley; Philip D Harvey
Journal:  Neuropsychology       Date:  2015-02-02       Impact factor: 3.295

3.  FAS and CFL forms of verbal fluency differ in difficulty: a meta-analytic study.

Authors:  Danielle Barry; Marsha E Bates; Erich Labouvie
Journal:  Appl Neuropsychol       Date:  2008

4.  Tests of information processing speed: what do people with multiple sclerosis think about them?

Authors:  Lisa A S Walker; Amy Cheng; Jason Berard; Lindsay I Berrigan; Laura M Rees; Mark S Freedman
Journal:  Int J MS Care       Date:  2012

5.  Predictors of the accuracy of self assessment of everyday functioning in people with schizophrenia.

Authors:  Samir Sabbag; Elizabeth W Twamley; Lea Vella; Robert K Heaton; Thomas L Patterson; Philip D Harvey
Journal:  Schizophr Res       Date:  2012-03-02       Impact factor: 4.939

6.  Self-assessment of functional status in schizophrenia.

Authors:  Christopher R Bowie; Elizabeth W Twamley; Hannah Anderson; Brooke Halpern; Thomas L Patterson; Philip D Harvey
Journal:  J Psychiatr Res       Date:  2006-10-02       Impact factor: 4.791

7.  The NEO-FFI in Multiple Sclerosis: internal consistency, factorial validity, and correspondence between self and informant reports.

Authors:  Eben S Schwartz; Benjamin P Chapman; Paul R Duberstein; Bianca Weinstock-Guttman; Ralph H B Benedict
Journal:  Assessment       Date:  2010-05-19

8.  Self-assessment of functional ability in schizophrenia: milestone achievement and its relationship to accuracy of self-evaluation.

Authors:  Felicia Gould; Samir Sabbag; Dante Durand; Thomas L Patterson; Philip D Harvey
Journal:  Psychiatry Res       Date:  2013-03-26       Impact factor: 3.222

9.  Effects of single dose mixed amphetamine salts--extended release on processing speed in multiple sclerosis: a double blind placebo controlled study.

Authors:  Sarah A Morrow; Heather Rosehart
Journal:  Psychopharmacology (Berl)       Date:  2015-08-21       Impact factor: 4.530

10.  Lisdexamfetamine dimesylate improves processing speed and memory in cognitively impaired MS patients: a phase II study.

Authors:  Sarah A Morrow; Audrey Smerbeck; Kara Patrick; Diane Cookfair; Bianca Weinstock-Guttman; Ralph H B Benedict
Journal:  J Neurol       Date:  2012-09-23       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.